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Background
The C5 region of HIV-1 gp120 has sequence homology
with both HLA class I and class II molecules. We have pre-
viously shown by UV cross linking that some peptides can
bind gp120. In this study, using gp120 mutants and enve-
lopes from a number of different HIV-1 and HIV-2 iso-
lates, we report the specificity of this finding and explore
the implications of these results for treatment.
Methods
We used mass spectrometry to determine the specific
binding of selected peptides to gp120 preparations, one of
which has the C5 region deleted. We also looked at the
three dimensional binding of a number of HIV-1 and
HIV-2 isolates.
Results
We show that HIV gp120 can bind peptides in a similar
manner to HLA molecules and that this property is con-
fined to the C5 region as the C5 deleted mutant has no
binding ability. Moreover, we show this as a property of
all HIV-1 isolates but not of HIV-2 isolates. Moreover, an
antibody to the C5 region is able to inhibit mixed lym-
phocytic reactions in keeping with the structural similarity
between this region and HLA.
Conclusion
The ability of the C5 region to bind peptides suggest that
its similarity with HLA could drive a chronic activation
process in certain HLA backgrounds. This property could
also explain the antigen specific anergy which is reported
prior to the decline in CD4 levels. We have previously
reported that exposed but non infected individuals have
high titre antibodies to this region and more recently it
has been reported that long term non progressors also
have high titre antibodies to this region. Although these
antibodies are non neutralising in standard virus neutral-
ization assays the antibodies may be able to neutralize the
activation and hence the pathogenesis of disease. There-
fore peptides from the C5 region could provide the basis
of a more effective therapeutic vaccine.
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